Etanercept biosimilar is under clinical development by Shilpa Biologicals and currently in Phase I for Psoriatic Arthritis. According to GlobalData, Phase I drugs for Psoriatic Arthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Etanercept biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Etanercept biosimilar overview
Etanercept biosimilar (SBDM-002) is under development for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. The drug candidate acts by targeting tumor necrosis factor (TNFR) receptor.
Shilpa Biologicals overview
Shilpa Biologicals, a subsidiary of Shilpa Medicare Ltd, a biotechnology research company which focuses on developing affordable biopharmaceuticals for patients with cutting-edge research and creative collaborations. The company is headquartered in Dharwad, Karnataka, India.
For a complete picture of Etanercept biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
